RB94 gene therapy

Drug Profile

RB94 gene therapy

Alternative Names: Ad-RB94

Latest Information Update: 22 Jun 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Baylor College of Medicine
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action Apoptosis stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Head and neck cancer; Lung cancer; Pancreatic cancer

Most Recent Events

  • 22 Jun 2007 Discontinued - Preclinical for Head and neck cancer in USA (unspecified route)
  • 22 Jun 2007 Discontinued - Preclinical for Lung cancer in USA (unspecified route)
  • 22 Jun 2007 Discontinued - Preclinical for Pancreatic cancer in Spain (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top